Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.

Moreno, C; Greil, R; Demirkan, F; Tedeschi, A; Anz, B; Larratt, L; Simkovic, M; Samoilova, O; Novak, J; Ben-Yehuda, D; Strugov, V; Gill, D; Gribben, JG; Hsu, E; Lih, CJ; Zhou, C; Clow, F; James, DF; Styles, L; Flinn, IW;

View this publication in the PUBMED database